Narcolepsy Therapeutics Market Snapshot
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The narcolepsy therapeutics market is anticipated to witness a CAGR of nearly 9.9% during the forecast period (2022-2027).
COVID-19 has significantly impacted the market growth due to decreased adoption of narcolepsy therapeutics during the pandemic. For instance, according to the study published in the Journal of Clinical Sleep Medicine, titled 'Sleeping through a pandemic: impact of COVID-19-related restrictions on narcolepsy and idiopathic hypersomnia' in January 2022. extended sleep time, circadian delay (in Idiopathic Hypersomnia patients), and teleworking all reduced central hypersomnia symptoms. This has impacted the growth of the narcotic therapeutics market as there has been decreased consumption of narcolepsy therapeutics due to adequate sleep by people.
The increasing prevalence of narcoleptic disorders across the world, rising stress levels, growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. For instance, in the Journal of Clinical Sleep Medicine, titled 'Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study' in January 2022, the early incidence of narcolepsy in Europe is 0.64-1.37 per 100,000. The high incidence of this disorder will lead to increased adoption of narcolepsy therapies, thereby expected to drive the market growth over the forecast period.
In addition, according to the study published in Current Sleep Medicine Reports, titled 'Narcolepsy Presentation in Diverse Populations: an Update' in November 2020, The results found that narcolepsy affects 0.87–1.21% of the world's population, specifically narcolepsy type 1 (NT1) being investigated. The rising prevalence of narcolepsy globally will lead to increased adoption of narcolepsy therapeutics in population to keep themselves active during the day, driving the market growth.
The approval and commercialization of new drugs by market players may also play a crucial role in driving market growth over the coming years. For instance, in March 2021, the United States Food and Drug Administration (FDA) accepted Avadel's New Drug Application (NDA) for FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
However, delayed diagnosis or misdiagnosis may hamper the demand in the narcolepsy therapeutics market.
Scope of the Report
Narcolepsy is a long-term neurological disorder involving decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Around 70% of people experience episodes of a sudden loss of muscle strength, known as cataplexy, which can also strongly affect the emotional state of patients. The Narcolepsy Therapeutics Market is segmented by Type (Cataplexy and Without Cataplexy), Product (Central Nervous System Stimulants, Sodium Oxybate, and Tricyclic Antidepressants), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
|Narcolepsy with Cataplexy|
|Narcolepsy without Cataplexy|
|Central Nervous System Stimulants|
|Selective Serotonin Reuptake Inhibitors|
Key Market Trends
Central Nervous System Stimulants Segment is Expected to Hold a Major Share During the Forecast Period
The Central Nervous System Stimulants segment is expected to hold a major share in the market during the forecast period.
According to an article published in CNS Drugs, titled 'Recently Approved and Upcoming Treatments for Narcolepsy', in January 2021, treatments such as modafinil, armodafinil, and other central nervous stimulants for narcolepsy are aimed at improving wakefulness in patients with narcolepsy.
Rising research on central nervous system stimulants is expected to drive the growth of this segment. For instance, in December 2021, Harmony Biosciences Holdings, Inc, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, published the data analysis of CNS Drugs that evaluate the time to onset of response to pitolisant for excessive daytime sleepiness (EDS) and cataplexy in adult narcolepsy patients. Such studies will lead to novel central system stimulants' development, thereby driving this segment's growth.
Furthermore, according to the study published in Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy, titled 'Narcolepsy Treatment: Present and Future' in October 2021, The combination of modafinil with connexin-30 inhibitors is under development as this generates a stimulant effect within the central nervous system (CNS). The rise in the development of CNS stimulants for narcolepsy will lead to novel combination molecules coming into the market, thereby driving market growth.
In addition, according to the study published in Neurotherapeutics, titled 'A practical guide to the pharmacological and behavioral therapy of Narcolepsy 'in April 2021, modafinil, a CNS stimulant, has been approved by the Food and Drugs Administration and the European Medicines Agency (EMA) for adult narcolepsy patients and is regarded a good therapy due to its low potential for addiction and mild adverse effects.
Therefore, owing to the advantages of CNS stimulants in the treatment of narcolepsy, this segment is expected to drive the market over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Market
North America is expected to hold a major share in the market studied during the forecast period.
This is owing to the growing demand for sleep disorder treatment in the United States and Canada. The increasing prevalence of narcoleptic disorders, increased awareness, and high healthcare spending is anticipated to drive the market. In addition, favorable reimbursement policies for therapeutic products, a strong clinical pipeline, and rising stress levels are the other factors anticipated to promote revenue growth.
According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. However, because this ailment is frequently misdiagnosed, the figure could be much higher. The high prevalence of narcolepsy in developed countries such as the United States will lead to increased adoption of narcolepsy therapeutics, thereby driving the market growth in this region.
Furthermore, according to the news published in September 2021, Stanford researcher has proved that once-nightly narcolepsy treatment is safe and effective as a phase 3 study demonstrated that an extended-release variant of sodium oxybate lowers daytime sleepiness and attacks muscle weakness in narcolepsy patients. Rising effective results of narcolepsy treatments in the United States will lead to increased adoption of these therapies, thereby driving the growth of this market in this region.
In addition, in December 2021, Wake Up Narcolepsy, the charity group, received USD 1 million in donations for neurological research illnesses such as narcolepsy. The rise in donations for the development of narcolepsy treatments in the United States is further expected to drive the growth of this market in this region in the future.
All these factors are anticipated to bode well for the regional market's growth in the forthcoming years.
To understand geography trends, Download Sample Report
The narcolepsy therapeutics market is moderately competitive. Collaborations and acquisitions to share technology and costs for innovation in the field are expected to be observed. The market is driven due to the development of novel therapies and approval by international regulatory agencies. Some of the major players include companies, such as Avadel Pharmaceuticals Inc., Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc., among others
· In March 2022, Axsome Therapeutics Inc. entered a definitive agreement to acquire Sunosi (solriamfetol), indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA) from Jazz Pharmaceuticals.
· In January 2022, the United States Food and Drug Administration (FDA) granted Orphan Drug Exclusivity (ODE) for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution developed by Jazz Pharmaceuticals for the treatment of idiopathic hypersomnia in adults.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of Narcolepsy
4.2.2 Narcolepsy Awareness Programs and Services
4.2.3 Presence of Reimbursement Policies Regarding Narcolepsy
4.3 Market Restraints
4.3.1 Adverse Effects and Risks Related to Narcolepsy Drugs
4.3.2 Delayed Diagnosis or Misdiagnosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1.1 Narcolepsy with Cataplexy
5.1.2 Narcolepsy without Cataplexy
5.1.3 Secondary Narcolepsy
5.2.1 Central Nervous System Stimulants
5.2.2 Sodium Oxybate
5.2.3 Selective Serotonin Reuptake Inhibitors
5.2.4 Tricyclic Antidepressants
5.2.5 Other Products
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Avadel Pharmaceuticals
6.1.2 Harmony Biosciences (BIOPROJET)
6.1.3 Jazz Pharmaceuticals PLC
6.1.4 Ligand Pharmaceuticals Incorporated
6.1.5 Novartis AG
6.1.6 Shionogi Inc.
6.1.7 Takeda Pharmaceutical Company
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Axsome Therapeutics Inc.
6.1.10 XWPharma Ltd.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Narcolepsy Therapeutics Market market is studied from 2019 - 2027.
What is the growth rate of Global Narcolepsy Therapeutics Market?
The Global Narcolepsy Therapeutics Market is growing at a CAGR of 9.9% over the next 5 years.
Which region has highest growth rate in Global Narcolepsy Therapeutics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Narcolepsy Therapeutics Market?
North America holds highest share in 2021.
Who are the key players in Global Narcolepsy Therapeutics Market?
Jazz Pharmaceuticals plc , Takeda Pharmaceutical Company , Teva Pharmaceuticals USA, Inc., Shionogi Inc, Novartis International AG are the major companies operating in Global Narcolepsy Therapeutics Market.